WT KSR1 mice treated with dabrafenib offered the same amount of protection as both KO KSR1 groups from cisplatin- and noise-induced hearing loss; therefore, dabrafenib is protecting through the MAPK pathway. Here, KSR1 is linked to hearing loss disorder.